Patent US1286429A successfully refreshed from Google Patents.
Patent US4460559A successfully refreshed from Google Patents.
US4460559A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
Assignee: Individual
•
Filing: 1982-05-04
•
Granted: 1984-07-17
•
Expires: 2002-05-04
Abstract
Abstract Methods are provided for using radiolabeled antibodies specific to intracellular tumor-associated markers for detection, localization and therapy of tumors. Antibodies and injectable compositions for use in the methods of the invention are also provided.
Inventors
- 👤 Milton D. Goldenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 21:34
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3007; A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1045; A61K51/1048; A61K2121/00; A61K2123/00; A61K38/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
94 words
A method for detecting and localizing a tumor which either produces or is associated with an intracellular marker substance, which comprises injecting a subject parenterally with an antibody specific to said marker substance and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, and subsequently scanning with said device to detect and locate the site or sites of uptake of said labeled antibody by said tumor; with the proviso that when said antibody is an antibody specific to human chlorionic gonadotropin or its beta-subunit, said radioisotope is other than Tc-99m.
Claim 2
Independent Claim
94 words
A method for detecting and localizing a tumor which either produces or is associated with an intracellular marker substance, which comprises injecting a subject parenterally with an antibody specific to said marker substance and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, and subsequently scanning with said device to detect and locate the site or sites of uptake of said labeled antibody by said tumor; with the proviso that when said antibody is an antibody specific to human chlorionic gonadotropin or its beta-subunit, said radioisotope is other than Tc-99m.
Claim 3
Dependent Claim
35 words
The method of claim 1, wherein said marker-specific antibody is a substantially monospecific antibody having a marker-specific immunoreactivity prior to labeling of at least 70% and a cross-reactivity to non-tumor-associated antigens of less than 15%.
Claim 4
Dependent Claim
14 words
The method of claim 2, wherein said substantially monospecific antibody is a monoclonal antibody.
Claim 5
Dependent Claim
24 words
The method of claim 2, wherein said antibody is radiolabeled to an extent sufficient to reduce its marker-specific immunoreactivity by from 5 to 33%.
Claim 6
Dependent Claim
41 words
The method of claim 4, wherein said substantially monospecific antibody is radiolabeled with Iodine-131 or Iodine-123, an average of at least 5 atoms of iodine per antibody molecule being introduced by direct substitution of iodine for hydrogen on the antibody molecule.
Claim 7
Dependent Claim
39 words
The method of claim 1, wherein said radioisotope is one of Iodine-131, Iodine-123, Iodine-126, Iodine-133, Bromine-77, Indium-111, Indium-113m, Gallium-67, Gallium-68, Ruthenium 95, Ruthenium-97, Ruthenium-103, Ruthenium-105, Mercury-107, Mercury-203, Rhenium-99m, Rhenium-105, Rhenium-101, Tellurium-121m, Tellurium-122m, Tellurium-125m, Thulium-165, Thulium-167, Thulium-168, Technetium-99m and Fluorine-18.
Claim 8
Dependent Claim
13 words
The method of claim 1, wherein said marker substance is an oncofetal antigen.
Claim 9
Dependent Claim
13 words
The method of claim 1, wherein said marker substance is a placental antigen.
Claim 10
Dependent Claim
17 words
The method of claim 1, wherein said marker substance is an oncogenic or tumor virus associated antigen.
Claim 11
Dependent Claim
25 words
The method of claim 1, wherein said marker substance is a tissue- or organ-associated antigen, an ectopic hormone or a normal antigen or variant thereof.
Claim 12
Dependent Claim
12 words
The method of claim 1, wherein said marker substance is alpha-fetoprotein (AFP).
Claim 13
Dependent Claim
23 words
The method of claim 1, wherein said marker substance is human chorionic gonadotropin (HCG) or its beta-subunit, said radioisotope being other than Tc-99m.
Claim 14
Dependent Claim
13 words
The method of claim 1, wherein said marker substance is colon-specific antigen-p (CSAp).
Claim 15
Dependent Claim
89 words
The method of claim 1, wherein said marker substance is one of prostatic acid phosphatase, pancreatic oncofetal antigen, placental alkaline phosphatase, pregnancy beta 1 -globulin, parathormone, calcitonin, tissue polypeptide antigen, T-antigen, beta 2 -microglobulin, galactosyl transferase-II (GT-II), gp-52 viral-associated antigen, ovarian cystadenocarcinoma-associated antigen (OCAA), ovarian tumor-specific antigen (OCA), cervica cancer antigens (CA-58, CCA, TA-4), basic fetoprotein (BFP), terminal deoxynucleotidyl transferase (TdT), cytoplasmic melonoma-associated antigens, human astrocytoma-associated antigen (HAAA), common glioma antigen (CGA), glioembryonic antigen (GEA), glial fibrillary acidic protein (GFA), common meningioma antigen (CMA) and tumor angiogenesis factor (TAF).
Claim 16
Dependent Claim
21 words
The method of claim 1, wherein said scanning is effected at least 8 hours after injection of said labeled specific antibody.
Claim 17
Dependent Claim
19 words
The method of claim 15, wherein said scanning is effected 8-24 hours after said injection of labeled specific antibody.
Claim 18
Dependent Claim
16 words
The method of claim 1, wherein said marker substance is other than HCG or its beta-subunit.
References Cited (Backward Citations)
US4323546A
Cited
US4361544A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-17 | 1988-01-16 | 1988-07-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-17 | 1992-01-16 | 1992-07-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-17 | 1996-01-16 | 1996-07-17 | $7700.00 | Window Closed / Lapsed |